Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB/II Study to Evaluate the Safety, Tolerability, and Efficacy of ASTX727 and FT-2102 in IDH1-Mutated Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT04013880 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT04013880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04013880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB/II Study to Evaluate the Safety, Tolerability, and Efficacy of ASTX727 and FT-2102 in IDH1-Mutated Myelodysplastic Syndrome or Acute Myeloid Leukemia
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 1/2
Overall status
Withdrawn
Start date
August 27, 2019
Completion date
March 31, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndrome, recurrent acute myeloid leukemia, recurrent myelodysplastic syndrome, refractory acute myeloid leukemia, refractory myelodysplastic syndrome